Journal
VECTOR-BORNE AND ZOONOTIC DISEASES
Volume 12, Issue 7, Pages 535-538Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/vbz.2012.1012
Keywords
Antibiotic therapy; C6 antibody; Ceftriaxone; Doxycycline; Erythema migrans; Lyme disease; Non-human primates; Post-treatment Lyme disease syndrome
Funding
- Centers for Disease Control and Prevention (CDC)
- National Institutes of Health (NIH)
- Immunetics, Inc.
- BioRad
- DiaSorin, Inc.
- BioMerieux
- NIH
- CDC
Ask authors/readers for more resources
A critical analysis of two treatment trials of Chinese rhesus macaques infected with Borrelia burgdorferi indicates that insufficient attention was placed on documenting the blood levels, pharmacokinetics, and pharmacodynamic parameters of the antibiotics used in this host. Consequently, it is impossible to conclude that the findings have validity in judging the efficacy of doxycycline or ceftriaxone for the treatment of Borrelia burgdorferi in this animal model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
